A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
191actual
Sites
2
Countries
Germany, United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-19 | actual | When the study began enrolling |
| Primary completion | 2026-06-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-22 | actual | The whole study's end, after follow-up |
| First posted | 2025-12-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: Andexanet alfa
- Drug: Rivaroxaban
- Drug: Apixaban
- Drug: Enoxaparin
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFAnti-Factor (F) Xa activity
measured Day 1 post dose
Change from baseline in anti-FXa activity
measured Day 1 post dose
Thrombin generation potential
measured Day 1 post dose
Change from pre-direct oral anticoagulants (DOAC) in thrombin generation potential
measured Day 1 post dose
Change from baseline in thrombin generation potential
measured Day 1 post dose
Time to onset of coagulation
measured Day 1 post dose
Change from pre-DOAC in time to onset of coagulation
measured Day 1 post dose
Change from baseline in time to onset of coagulation
measured Day 1 post dose
Anti-FXa activity following enoxaparin dosing
measured From Day 1 to Day 2
Thrombin generation potential following enoxaparin dosing
measured From Day 1 to Day 2
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed